VictoriaLBae-JumpMD

Obstetrics & Gynecology • Chapel Hill, NC

Gynecologic Oncology, Hospice & Palliative Medicine

Assistant Professor, Obstetrics & Gynecology, University of North Carolina at Chapel Hill School of Medicine

Join to view full profile

Dr. Bae-Jump is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Bae-Jump's full profile

Already have an account?

Office
101 Manning Dr
Rm 1107G
Chapel Hill, NC 27514
Phone+1 919-966-1072

Fax+1 919-966-0290

Education & Training

University of North Carolina HospitalsResidency, Obstetrics and Gynecology, 2000 - 2004
Virginia Commonwealth University School of MedicineClass of 2000

Certifications & Licensure

NC State Medical License 2000 - 2025
American Board of Internal Medicine Hospice and Palliative Medicine
American Board of Obstetrics and Gynecology Obstetrics & Gynecology
American Board of Obstetrics and Gynecology Gynecologic Oncology

Awards, Honors, & Recognition

Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Fellow (FACOG) American Congress of Obstetricians and Gynecologists

Clinical Trials

Metformin for the Treatment of Endometrial Hyperplasia Start of enrollment: 2013 Jan 10
Completed
Early Phase 1
Hybrid PET/MR in the Therapy of Cervical Cancer Start of enrollment: 2012 Oct 01
Completed
Metformin With the Levonorgestrel-Releasing Intrauterine Device for the Treatment of Complex Atypical Hyperplasia (CAH) and Endometrial Cancer (EC) in Non-surgical Patients Start of enrollment: 2014 Feb 27
Completed
Phase 2
Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer Start of enrollment: 2014 Mar 17
Active, not recruiting
Phase 2, Phase 3
Window of Opportunity Pilot Study of Pembrolizumab in Obesity-driven Endometrial Cancer Start of enrollment: 2019 Mar 29
Terminated
Early Phase 1
High Intensity Interval Training in Endometrial Cancer Start of enrollment: 2019 May 20
Active, not recruiting
Not Applicable
Join now to see all

Publications & Presentations

PubMed

6 citations
The Effects of NT-1044, a Novel AMPK Activator, on Endometrial Cancer Cell Proliferation, Apoptosis, Cell Stress and In Vivo Tumor Growth
Dario R. Roque, Lu Zhang, Weiya Z. Wysham, Jianjun Han, Wenchuan Sun
Frontiers in Oncology. 2021-08-05
4 citations
Inhibition of CDK1 by RO-3306 Exhibits Anti-Tumorigenic Effects in Ovarian Cancer Cells and a Transgenic Mouse Model of Ovarian Cancer.
Yu Huang, Yali Fan, Ziyi Zhao, Xin Zhang, Katherine Tucker
International Journal of Molecular Sciences. 2023-08-03
5 citations
Ipatasertib, an oral AKT inhibitor, in combination with carboplatin exhibits anti-proliferative effects in uterine serous carcinoma.
Wesley C Burkett, Ziyi Zhao, Meredith A Newton, Wenchuan Sun, Boer Deng
Annals of Medicine. 2023-12-01

Press Mentions

Uterine Cancer Cases Rising, Outcomes Worsening Especially for Black WomenJuly 26th, 2022
Shop TalkAugust 25th, 2017
Researchers Leverage AI to Develop Early Diagnostic Test for Ovarian CancerJanuary 30th, 2024
Join now to see all

Professional Memberships